logo
logo

Personal Genome Diagnostics Announces Close of $103 Million Series C Financing

Feb 10, 2021•over 4 years ago

Amount Raised

$103 Million

Round Type

series c

Baltimore

Description

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the close of a $103 million Series C financing. The financing was led by Cowen Healthcare Investments and joined by new and existing investors including Northpond Ventures, Vensana Capital, Rock Springs Capital, Kern Capital, Sands Capital, PFM Health Sciences, Windham Ventures, New Enterprise Associates, Innovatus Capital Partners, Catalio Capital Management, and others. Concurrent with the financing, Kevin Raidy, Managing Partner of Cowen Healthcare Investments, and Lily Li, Principal with Northpond Ventures, have joined the PGDx Board of Directors.

Company Information

Company

Personal Genome Diagnostics

Location

Baltimore, Maryland, United States

About

Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for health systems worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. For additional information, visit www.pgdx.com.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech